Aryeh Jason
SEC-identified person · CIK 1376960 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Orchestra Biomed Holdings, Inc. OBIO | Director | filed 2023 - 2026 |
| Ligand Pharmaceuticals INC LGNDD | Director | filed 2006 - 2026 |
| Lifecore Biomedical, INC. \DE\ LNDC | Director | filed 2024 - 2026 |
| Anebulo Pharmaceuticals, Inc. ANEB | Director | filed 2021 - 2025 |
| Merrimack Pharmaceuticals INC MACK | Officer | filed 2019 - 2019 |
| Aralez Pharmaceuticals Inc. ARLZ | Director | filed 2016 - 2017 |
| QLT INC/BC QLTI | Director | filed 2012 - 2017 |
| Immunomedics INC IMMU | Director | filed 2017 - 2017 |
| Myriad Pharmaceuticals, Inc. myrx | Director | filed 2011 - 2012 |
| Vaxart, Inc. VXRT | Director | filed 2006 - 2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.